

Proposal Subject:	<i>Vibrio vulnificus</i> Management Plan
Specific NSSP Guide Reference:	Section IV. Guidance Documents Chapter IV. Naturally Occurring Pathogens .02 <i>Vibrio vulnificus</i> Management Plan
Key Words:	<i>Vibrio vulnificus</i> ; <i>Vibrio vulnificus</i> Management Plan; Source States
Text of Proposal/ Requested Action:	<i>Vibrio vulnificus</i> source states are those states reporting two (2) or more etiologically confirmed shellfish-borne <i>Vibrio vulnificus</i> illnesses <u>in the previous five (5) years since 1995</u> traced to the consumption of commercially harvested raw or undercooked oysters that originated from the waters of that state.
Public Health Significance:	Currently there is no path for a state to be removed from the list of Illness Source States. The proposed change would alter the definition of <i>Vibrio vulnificus</i> Source State to remove states that have not had an illness for five (5) years.
Cost Information (if available):	None available.
Action by 2011 Task Force II	Recommended adoption of Proposal 11-204 as amended contingent upon Proposal 11-201A being voted no action or referred to committee. Add in NSSP Guide reference that this be included in Chapter II. @ .04 (effective January 1, 2012) A. <i>Vibrio vulnificus</i> source states are those states reporting two (2) or more etiologically confirmed shellfish-borne <i>Vibrio vulnificus</i> illnesses in the previous five (5) years since 1995 traced to the consumption of commercially harvested raw or undercooked oysters that originated from the waters of that state. <u><i>Vibrio vulnificus</i> Source States are those states reporting two (2) or more etiologically confirmed, and epidemiologically linked <i>Vibrio vulnificus</i> septicemia illnesses from the consumption of commercially harvested raw or undercooked oysters that originated from the growing waters of that state within the previous ten (10) years.</u>
Action by 2011 General Assembly	No action was taken on Proposal 11-204. Rationale: This proposal was addressed by General Assembly action on Proposal 11-201A.
Action by FDA February 26, 2012	Concurred with Conference action on Proposal 11-204.